Go Pro
→ Earth's biggest energy source: near Grand Canyon (From Behind the Markets) (Ad)tc pixel Free KOD Stock Alerts

Kodiak Sciences (KOD) Competitors

Kodiak Sciences logo
$32.89 +0.02 (+0.06%)
Closing price 09/11/2026 04:00 PM Eastern
Extended Trading
$33.50 +0.61 (+1.85%)
As of 09/11/2026 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

KOD vs. IBRX, TGTX, APGE, IMVT, and SYRE

Should you buy Kodiak Sciences stock or one of its competitors? Kodiak Sciences's main competitors and comparable companies include ImmunityBio (IBRX), TG Therapeutics (TGTX), Apogee Therapeutics (APGE), Immunovant (IMVT), and Spyre Therapeutics (SYRE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Kodiak Sciences compare to ImmunityBio?

ImmunityBio (NASDAQ:IBRX) and Kodiak Sciences (NASDAQ:KOD) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, profitability, valuation, risk and institutional ownership.

Kodiak Sciences has a net margin of 0.00% compared to ImmunityBio's net margin of -598.55%. ImmunityBio's return on equity of 0.00% beat Kodiak Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
ImmunityBio-598.55% N/A -51.65%
Kodiak Sciences N/A -273.23%-85.48%

In the previous week, ImmunityBio had 3 more articles in the media than Kodiak Sciences. MarketBeat recorded 7 mentions for ImmunityBio and 4 mentions for Kodiak Sciences. Kodiak Sciences' average media sentiment score of 1.44 beat ImmunityBio's score of 0.78 indicating that Kodiak Sciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ImmunityBio
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
2 Very Negative mention(s)
Positive
Kodiak Sciences
3 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

ImmunityBio has a beta of 0.04, meaning that its stock price is 96% less volatile than the broader market. Comparatively, Kodiak Sciences has a beta of 2.18, meaning that its stock price is 118% more volatile than the broader market.

Kodiak Sciences has lower revenue, but higher earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than Kodiak Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunityBio$165.79M50.57-$351.40M-$0.97N/A
Kodiak SciencesN/AN/A-$229.97M-$4.19N/A

8.6% of ImmunityBio shares are owned by institutional investors. Comparatively, 89.1% of Kodiak Sciences shares are owned by institutional investors. 66.1% of ImmunityBio shares are owned by company insiders. Comparatively, 44.4% of Kodiak Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

ImmunityBio currently has a consensus target price of $14.20, indicating a potential upside of 79.52%. Kodiak Sciences has a consensus target price of $48.14, indicating a potential upside of 46.38%. Given ImmunityBio's stronger consensus rating and higher probable upside, equities research analysts clearly believe ImmunityBio is more favorable than Kodiak Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ImmunityBio
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.71
Kodiak Sciences
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.63

Summary

ImmunityBio beats Kodiak Sciences on 8 of the 14 factors compared between the two stocks.

How does Kodiak Sciences compare to TG Therapeutics?

Kodiak Sciences (NASDAQ:KOD) and TG Therapeutics (NASDAQ:TGTX) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation.

Kodiak Sciences has a beta of 2.18, indicating that its share price is 118% more volatile than the broader market. Comparatively, TG Therapeutics has a beta of 1.67, indicating that its share price is 67% more volatile than the broader market.

TG Therapeutics has a net margin of 55.22% compared to Kodiak Sciences' net margin of 0.00%. TG Therapeutics' return on equity of 73.49% beat Kodiak Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Kodiak SciencesN/A -273.23% -85.48%
TG Therapeutics 55.22%73.49%34.14%

In the previous week, TG Therapeutics had 5 more articles in the media than Kodiak Sciences. MarketBeat recorded 9 mentions for TG Therapeutics and 4 mentions for Kodiak Sciences. Kodiak Sciences' average media sentiment score of 1.44 beat TG Therapeutics' score of 0.92 indicating that Kodiak Sciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Kodiak Sciences
3 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
TG Therapeutics
5 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Kodiak Sciences currently has a consensus target price of $48.14, suggesting a potential upside of 46.38%. TG Therapeutics has a consensus target price of $63.00, suggesting a potential upside of 16.90%. Given Kodiak Sciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Kodiak Sciences is more favorable than TG Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kodiak Sciences
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.63
TG Therapeutics
2 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.33

TG Therapeutics has higher revenue and earnings than Kodiak Sciences. Kodiak Sciences is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kodiak SciencesN/AN/A-$229.97M-$4.19N/A
TG Therapeutics$616.29M13.38$447.18M$2.7419.67

89.1% of Kodiak Sciences shares are owned by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are owned by institutional investors. 44.4% of Kodiak Sciences shares are owned by company insiders. Comparatively, 8.9% of TG Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

TG Therapeutics beats Kodiak Sciences on 8 of the 15 factors compared between the two stocks.

How does Kodiak Sciences compare to Apogee Therapeutics?

Apogee Therapeutics (NASDAQ:APGE) and Kodiak Sciences (NASDAQ:KOD) are both mid-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, analyst recommendations, media sentiment, dividends, earnings and risk.

Apogee Therapeutics is trading at a lower price-to-earnings ratio than Kodiak Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Apogee TherapeuticsN/AN/A-$255.84M-$4.34N/A
Kodiak SciencesN/AN/A-$229.97M-$4.19N/A

Apogee Therapeutics currently has a consensus price target of $126.77, suggesting a potential downside of 6.14%. Kodiak Sciences has a consensus price target of $48.14, suggesting a potential upside of 46.38%. Given Kodiak Sciences' stronger consensus rating and higher possible upside, analysts clearly believe Kodiak Sciences is more favorable than Apogee Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Apogee Therapeutics
1 Sell rating(s)
15 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.16
Kodiak Sciences
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.63

Apogee Therapeutics has a beta of 0.33, indicating that its share price is 67% less volatile than the broader market. Comparatively, Kodiak Sciences has a beta of 2.18, indicating that its share price is 118% more volatile than the broader market.

In the previous week, Apogee Therapeutics had 5 more articles in the media than Kodiak Sciences. MarketBeat recorded 9 mentions for Apogee Therapeutics and 4 mentions for Kodiak Sciences. Apogee Therapeutics' average media sentiment score of 1.70 beat Kodiak Sciences' score of 1.44 indicating that Apogee Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Apogee Therapeutics
8 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Kodiak Sciences
3 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

79.0% of Apogee Therapeutics shares are owned by institutional investors. Comparatively, 89.1% of Kodiak Sciences shares are owned by institutional investors. 24.3% of Apogee Therapeutics shares are owned by insiders. Comparatively, 44.4% of Kodiak Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Apogee Therapeutics' return on equity of -29.88% beat Kodiak Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Apogee TherapeuticsN/A -29.88% -28.08%
Kodiak Sciences N/A -273.23%-85.48%

Summary

Kodiak Sciences beats Apogee Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Kodiak Sciences compare to Immunovant?

Immunovant (NASDAQ:IMVT) and Kodiak Sciences (NASDAQ:KOD) are both mid-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends.

Immunovant is trading at a lower price-to-earnings ratio than Kodiak Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunovantN/AN/A-$505.61M-$2.82N/A
Kodiak SciencesN/AN/A-$229.97M-$4.19N/A

Immunovant presently has a consensus price target of $44.00, indicating a potential upside of 17.77%. Kodiak Sciences has a consensus price target of $48.14, indicating a potential upside of 46.38%. Given Kodiak Sciences' stronger consensus rating and higher possible upside, analysts clearly believe Kodiak Sciences is more favorable than Immunovant.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Immunovant
1 Sell rating(s)
3 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.55
Kodiak Sciences
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.63

In the previous week, Immunovant had 1 more articles in the media than Kodiak Sciences. MarketBeat recorded 5 mentions for Immunovant and 4 mentions for Kodiak Sciences. Kodiak Sciences' average media sentiment score of 1.44 beat Immunovant's score of 1.43 indicating that Kodiak Sciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Immunovant
3 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Kodiak Sciences
3 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Immunovant has a beta of 0.81, indicating that its stock price is 19% less volatile than the broader market. Comparatively, Kodiak Sciences has a beta of 2.18, indicating that its stock price is 118% more volatile than the broader market.

Immunovant's return on equity of -69.59% beat Kodiak Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
ImmunovantN/A -69.59% -62.49%
Kodiak Sciences N/A -273.23%-85.48%

47.1% of Immunovant shares are owned by institutional investors. Comparatively, 89.1% of Kodiak Sciences shares are owned by institutional investors. 1.9% of Immunovant shares are owned by insiders. Comparatively, 44.4% of Kodiak Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Kodiak Sciences beats Immunovant on 8 of the 13 factors compared between the two stocks.

How does Kodiak Sciences compare to Spyre Therapeutics?

Spyre Therapeutics (NASDAQ:SYRE) and Kodiak Sciences (NASDAQ:KOD) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

Spyre Therapeutics presently has a consensus price target of $109.69, suggesting a potential upside of 21.07%. Kodiak Sciences has a consensus price target of $48.14, suggesting a potential upside of 46.38%. Given Kodiak Sciences' higher possible upside, analysts clearly believe Kodiak Sciences is more favorable than Spyre Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Spyre Therapeutics
1 Sell rating(s)
1 Hold rating(s)
12 Buy rating(s)
1 Strong Buy rating(s)
2.87
Kodiak Sciences
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.63

In the previous week, Spyre Therapeutics had 13 more articles in the media than Kodiak Sciences. MarketBeat recorded 17 mentions for Spyre Therapeutics and 4 mentions for Kodiak Sciences. Kodiak Sciences' average media sentiment score of 1.44 beat Spyre Therapeutics' score of 0.70 indicating that Kodiak Sciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Spyre Therapeutics
5 Very Positive mention(s)
3 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Kodiak Sciences
3 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Spyre Therapeutics has a beta of 2.99, meaning that its stock price is 199% more volatile than the broader market. Comparatively, Kodiak Sciences has a beta of 2.18, meaning that its stock price is 118% more volatile than the broader market.

80.4% of Spyre Therapeutics shares are held by institutional investors. Comparatively, 89.1% of Kodiak Sciences shares are held by institutional investors. 15.7% of Spyre Therapeutics shares are held by insiders. Comparatively, 44.4% of Kodiak Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Spyre Therapeutics' return on equity of -30.74% beat Kodiak Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Spyre TherapeuticsN/A -30.74% -22.23%
Kodiak Sciences N/A -273.23%-85.48%

Spyre Therapeutics is trading at a lower price-to-earnings ratio than Kodiak Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Spyre TherapeuticsN/AN/A-$155.20M-$1.95N/A
Kodiak SciencesN/AN/A-$229.97M-$4.19N/A

Summary

Spyre Therapeutics beats Kodiak Sciences on 9 of the 14 factors compared between the two stocks.

Get Kodiak Sciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for KOD and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KOD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

KOD vs. The Competition

Export
MetricKodiak SciencesBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$2.07B$3.84B$7.15B$12.72B
Dividend YieldN/A3.63%2.56%11.15%
P/E Ratio-7.8514.25275.2425.29
Price / SalesN/A1,473.16656.0298.94
Price / CashN/A106.6877.0451.44
Price / Book11.0715.1210.336.20
Net Income-$229.97M-$22.86M$3.50B$358.50M
7 Day Performance-6.99%-4.34%-3.32%-2.35%
1 Month Performance-24.23%-0.02%-0.41%-2.77%
1 Year Performance255.57%40.64%19.21%7.63%

Kodiak Sciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
KOD
Kodiak Sciences
2.1082 of 5 stars		$32.89
+0.1%		$48.14
+46.4%		+231.6%$2.07BN/AN/A124
IBRX
ImmunityBio
2.1749 of 5 stars		$8.15
+0.9%		$14.20
+74.2%		+205.4%$8.70B$113.29MN/A590
TGTX
TG Therapeutics
3.3939 of 5 stars		$55.41
-1.0%		$63.00
+13.7%		+66.0%$8.49B$616.29M20.24290
APGE
Apogee Therapeutics
1.7138 of 5 stars		$135.07
flat		$126.77
-6.1%		N/A$8.40BN/AN/A91
IMVT
Immunovant
2.6441 of 5 stars		$39.49
+0.6%		$44.00
+11.4%		+122.4%$8.18BN/AN/A120

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:KOD) was last updated on 9/12/2026 by MarketBeat.com Staff.
From Our Partners
The retirement stock I'd buy before Nvidia today
In 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...
Chaikin Analytics | Sponsoredtc pixel
Why the Treasury still prices gold at 42 dollars an ounce
The U.S. Treasury still values its gold reserves at 42.22 dollars an ounce, a price set in 1973. Gold trades n...
Golden Portfolio | Sponsoredtc pixel
How options let you do more with less capital
Would you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...
Base Camp Trading | Sponsoredtc pixel
This 38 Dollar Fund Holds Every Major AI Stock and Pays Weekly
The biggest AI stocks like Nvidia, CrowdStrike, and Palantir now trade for hundreds of dollars a share. One fu...
Investors Alley | Sponsoredtc pixel
Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
He turned $12K into $1.65M without touching Apple or Tesla
Tim Sykes turned $12,415 in gift money into more than $1.65 million before graduating college, without trading...
Tim Sykes | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
17 Nobel Prize winners… one startling warning
On July 13, 17 Nobel laureates including Bernanke, Krugman, and Stiglitz signed an 88-word letter warning that...
Porter & Company | Sponsoredtc pixel